TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients
TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients
复制标题
DOI：
10.1007/s00432-015-2054-7
复制
发表时间：
2016-03-01
影响因子：
3.6
通讯作者：
Castel, Victoria
中科院分区：
文献类型：
--
作者：
Yanez, Yania;Hervas, David;Castel, Victoria
目的在转移性神经母细胞瘤（NB）患者中，准确的危险分层和疾病监测将降低复发概率。本研究旨在评估通过逆转录酶定量聚合酶链反应（RT-qPCR）检测来自转移性NB患者的外周血（PB）和骨髓（BM）样品中的酪氨酸羟化酶（TH）和双皮质素（DCX）mRNA的独立预后意义。结果在一组162例转移性NB中，诊断时PB和BM中TH和DCX mRNA的高水平独立预测预后不良。在高危转移性NB亚组中，PB中检测到的TH mRNA仍然是诊断时EFS和OS的独立预测因子。诱导治疗后，PB中TH mRNA和BM中DCX mRNA的高水平独立预测EFS和OS较差。此外，BM中检测到TH mRNA时，预测EFS较差。结论RT-qPCR检测PB和BM中TH和DCX的mRNA水平，可作为评估转移性NB患者预后差异的新的治疗前风险分层策略。在那些高危转移性NB中，TH和DCX mRNA定量可用于评估对治疗的反应和早期检测疾病进展或复发。
Purpose In metastatic neuroblastoma (NB) patients, accurate risk stratification and disease monitoring would reduce relapse probabilities. This study aims to evaluate the independent prognostic significance of detecting tyrosine hydroxylase (TH) and doublecortin (DCX) mRNAs by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) in peripheral blood (PB) and bone marrow (BM) samples from metastatic NB patients.Procedures RT-qPCR was performed on PB and BM samples from metastatic NB patients at diagnosis, post-induction therapy and at the end of treatment for TH and DCX mRNAs detection.Results High levels of TH and DCX mRNAs when detected in PB and BM at diagnosis independently predicted worse outcome in a cohort of 162 metastatic NB. In the subgroup of high-risk metastatic NB, TH mRNA detected in PB remained as independent predictor of EFS and OS at diagnosis. After the induction therapy, high levels of TH mRNA in PB and DCX mRNA in BM independently predicted poor EFS and OS. Furthermore TH mRNA when detected in BM predicted worse EFS. TH mRNA in PB samples at the end of treatment is an independent predictor of worse outcome.Conclusion TH and DCX mRNAs levels in PB and BM assessed by RT-qPCR should be considered in new pre-treatment risk stratification strategies to reliable estimate outcome differences in metastatic NB patients. In those high-risk metastatic NB, TH and DCX mRNA quantification could be used for the assessment of response to treatment and for early detection of progressive disease or relapses.